Stemline Therapeutics Company Profile (NASDAQ:STML)

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:STML
  • CUSIP: N/A
  • Web: www.stemline.com
Capitalization:
  • Market Cap: $192.85 million
  • Outstanding Shares: 23,376,000
Average Prices:
  • 50 Day Moving Avg: $8.42
  • 200 Day Moving Avg: $9.80
  • 52 Week Range: $5.44 - $14.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.27
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.14 million
  • Price / Sales: 169.17
  • Book Value: $3.99 per share
  • Price / Book: 2.07
Profitability:
  • EBIDTA: ($44,340,000.00)
  • Net Margins: -4,058.44%
  • Return on Equity: -50.06%
  • Return on Assets: -44.60%
Debt:
  • Current Ratio: 5.60%
  • Quick Ratio: 5.60%
Misc:
  • Average Volume: 234,587 shs.
  • Beta: 0.13
  • Short Ratio: 3.69
 

Frequently Asked Questions for Stemline Therapeutics (NASDAQ:STML)

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.67) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.22. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. Stemline Therapeutics had a negative net margin of 4,058.44% and a negative return on equity of 50.06%. View Stemline Therapeutics' Earnings History.

Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?

6 brokers have issued 12 month price targets for Stemline Therapeutics' shares. Their predictions range from $16.00 to $41.00. On average, they anticipate Stemline Therapeutics' stock price to reach $32.60 in the next year. View Analyst Ratings for Stemline Therapeutics.

What are analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:

  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (5/20/2017)
  • 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
  • 3. Cowen and Company analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)
  • 4. Jefferies Group LLC analysts commented, "We had a chance to host investor meetings with mgmt, which primarily focused on near-term SL-401 catalysts. In BPDCN, the focus was around the pot’l 2H16 meeting with FDA to determine the amount of data needed to submit a BLA. The company also presented incrementally updated data in BPDCN that was consistent with data from ASCO." (7/22/2016)

Who are some of Stemline Therapeutics' key competitors?

Who owns Stemline Therapeutics stock?

Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.14%), Eventide Asset Management LLC (4.33%), Vanguard Group Inc. (4.60%), AXA (2.42%), Sphera Funds Management LTD. (1.67%) and VHCP Management II LLC (1.27%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

Who sold Stemline Therapeutics stock? Who is selling Stemline Therapeutics stock?

Stemline Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Morgan Stanley, Dimensional Fund Advisors LP and Stoneridge Investment Partners LLC. Company insiders that have sold Stemline Therapeutics stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.

Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?

Stemline Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, AXA, Sphera Funds Management LTD., Eventide Asset Management LLC, Vanguard Group Inc., Columbus Circle Investors, Cowen Group Inc. and Trexquant Investment LP. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy Stemline Therapeutics stock?

Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Stemline Therapeutics stock cost?

One share of Stemline Therapeutics stock can currently be purchased for approximately $8.25.

Analyst Ratings

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.60 (295.15% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017HC WainwrightReiterated RatingBuyMediumView Rating Details
5/12/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
5/11/2017WedbushBoost Price TargetOutperform$33.00 -> $40.00HighView Rating Details
3/20/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$41.00MediumView Rating Details
2/3/2017Jefferies Group LLCSet Price TargetBuy$16.00N/AView Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/AView Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Stemline Therapeutics (NASDAQ:STML)
Earnings by Quarter for Stemline Therapeutics (NASDAQ:STML)
Earnings History by Quarter for Stemline Therapeutics (NASDAQ:STML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.45)($0.67)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)$0.15 million$0.21 millionViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)$0.10 million$0.21 millionViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)$0.10 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)$0.09 million$0.12 millionViewN/AView Earnings Details
3/13/2015($0.60)($0.53)$0.07 million$0.12 millionViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)$0.07 million$0.07 millionViewN/AView Earnings Details
8/14/2014($0.71)($0.47)$0.07 million$0.07 millionViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
2017 EPS Consensus Estimate: ($1.98)
2018 EPS Consensus Estimate: ($1.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.48)($0.48)($0.48)
Q4 20171($0.61)($0.61)($0.61)
Q1 20181($0.38)($0.38)($0.38)
Q2 20181($0.38)($0.38)($0.38)
Q3 20181($0.39)($0.39)($0.39)
Q4 20181($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Stemline Therapeutics (NASDAQ:STML)
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 37.76%
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/28/2017David GioncoInsiderSell6,486$6.99$45,337.14View SEC Filing  
2/28/2017Ivan BergsteinCEOSell17,980$6.99$125,680.20View SEC Filing  
2/28/2017Kenneth HobermanCOOSell8,027$6.99$56,108.73View SEC Filing  
2/27/2017David GioncoCAOSell3,500$6.97$24,395.00View SEC Filing  
2/27/2017Ivan BergsteinCEOSell7,500$6.97$52,275.00View SEC Filing  
2/27/2017Kenneth HobermanCOOSell4,000$6.97$27,880.00View SEC Filing  
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Stemline Therapeutics (NASDAQ:STML)
Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
Source:
DateHeadline
americanbankingnews.com logoStemline Therapeutics Inc (STML) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 20 at 7:08 AM
streetinsider.com logoStemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA
www.streetinsider.com - May 19 at 12:51 PM
streetinsider.com logoStemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 ... - StreetInsider.com
www.streetinsider.com - May 18 at 12:55 PM
finance.yahoo.com logoStemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting
finance.yahoo.com - May 18 at 12:55 PM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc.
finance.yahoo.com - May 16 at 7:59 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 15 at 4:28 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 11:22 AM
americanbankingnews.com logoBrokers Offer Predictions for Stemline Therapeutics Inc's Q2 2017 Earnings (STML)
www.americanbankingnews.com - May 15 at 7:26 AM
americanbankingnews.com logoAnalysts Offer Predictions for Stemline Therapeutics Inc's Q1 2018 Earnings (STML)
www.americanbankingnews.com - May 12 at 4:08 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - May 12 at 1:38 PM
americanbankingnews.com logoWedbush Reaffirms Outperform Rating for Stemline Therapeutics Inc (STML)
www.americanbankingnews.com - May 11 at 5:24 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 4:29 PM
globenewswire.com logoStemline Therapeutics Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 1:19 AM
finance.yahoo.com logoStemline Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 1:19 AM
finance.yahoo.com logoStemline Therapeutics reports 1Q loss
finance.yahoo.com - May 11 at 1:19 AM
americanbankingnews.com logoFavorable News Coverage Extremely Likely to Affect Stemline Therapeutics (STML) Stock Price
www.americanbankingnews.com - May 3 at 11:22 AM
finance.yahoo.com logoJ&W Investigates Investment Technology Group (ITG) and Stemline Therapeutics (STML); Should Officers and Directors be Responsible for Alleged Harm to the Company?
finance.yahoo.com - May 3 at 10:35 AM
finance.yahoo.com logoStemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 1 at 11:23 AM
americanbankingnews.com logoStemline Therapeutics (STML) Getting Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 5:45 PM
americanbankingnews.com logoStemline Therapeutics (STML) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 8:46 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Novan, Stemline Therapeutics, BioDelivery Sciences, and ... - PR Newswire (press release)
www.prnewswire.com - April 25 at 9:35 AM
americanbankingnews.com logoStemline Therapeutics (STML) Receives Daily News Sentiment Score of 0.16
www.americanbankingnews.com - April 24 at 7:22 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Stemline Therapeutics (STML) Stock Price
www.americanbankingnews.com - April 21 at 11:00 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 21 at 7:24 PM
americanbankingnews.com logoStemline Therapeutics (STML) Given Daily News Impact Score of 0.23
www.americanbankingnews.com - April 18 at 3:38 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 12:28 PM
americanbankingnews.com logoStemline Therapeutics (STML) Given Media Impact Score of 0.23
www.americanbankingnews.com - April 15 at 3:17 PM
finance.yahoo.com logoDEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML
finance.yahoo.com - April 3 at 7:47 PM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - April 3 at 7:47 PM
finance.yahoo.com logoDEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 3 at 7:47 PM
finance.yahoo.com logoSTEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND …
finance.yahoo.com - April 1 at 10:14 AM
globenewswire.com logoUPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
finance.yahoo.com logoApril 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoDEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoSTML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoUPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 3:20 PM
finance.yahoo.com logoAPRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, …
finance.yahoo.com - March 31 at 1:30 AM
us.rd.yahoo.com logoDeadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc.
us.rd.yahoo.com - March 31 at 1:30 AM
feeds.benzinga.com logoAPRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - March 30 at 10:06 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - March 30 at 8:29 PM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 8:29 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 2:07 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Stemline Therapeutics, Inc.
finance.yahoo.com - March 28 at 7:55 PM
americanbankingnews.com logoStemline Therapeutics Inc (STML) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 28 at 12:28 PM
americanbankingnews.com logoShort Interest in Stemline Therapeutics Inc (STML) Grows By 43.3%
www.americanbankingnews.com - March 28 at 7:13 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 27 at 7:14 PM
americanbankingnews.com logoStemline Therapeutics' (STML) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 25 at 10:59 AM
streetinsider.com logoStemline Therapeutics (STML) Completes Enrollment in Stage 3 of ... - StreetInsider.com
www.streetinsider.com - March 25 at 5:40 AM
finance.yahoo.com logoSTEMLINE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Stemline Therapeutics, Inc. – (STML)
finance.yahoo.com - March 25 at 5:40 AM

Social

Chart

Stemline Therapeutics (STML) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff